
ELV Earnings
Elevance Health Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Elevance Health Inc(ELV) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Elevance Health Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-07-17 | Pre-Market | 9.14 | 8.84 | -3.28 | 48.20B | 49.42B | +2.54 | -12.22 | -18.24 |
FY2025Q1 | 2025-04-22 | Pre-Market | 11.97 | 11.97 | - | 46.25B | 48.77B | +5.44 | +2.26 | +3.69 |
FY2024Q4 | 2025-01-23 | Pre-Market | 3.80 | 3.84 | +1.05 | 44.72B | 44.99B | +0.61 | +2.72 | +2.45 |
FY2024Q3 | 2024-10-17 | Pre-Market | 9.70 | 8.37 | -13.71 | 43.14B | 44.72B | +3.66 | -10.59 | -16.38 |
FY2024Q2 | 2024-07-17 | - | 9.99 | 10.12 | +1.30 | 42.90B | 43.22B | +0.75 | -5.82 | -9.17 |
FY2024Q1 | 2024-04-18 | - | 10.54 | 10.64 | +0.95 | 42.44B | 42.27B | -0.40 | +3.19 | +4.86 |
FY2023Q4 | 2024-01-24 | - | 5.55 | 5.62 | +1.26 | 42.20B | 42.45B | +0.59 | +0.32 | +4.28 |
FY2023Q3 | 2023-10-18 | - | 8.45 | 8.99 | +6.39 | 42.72B | 42.48B | -0.57 | +0.78 | -2.81 |
- | 2023-07-19 | - | 8.82 | 9.04 | +2.49 | - | - | - | +4.40 | +7.25 |
- | 2023-04-19 | - | 9.26 | 9.46 | +2.16 | - | - | - | -5.33 | -4.60 |
ELV Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Elevance Health Inc reported performance for FY2025Q2, announced on 2025-07-17. The company achieved an EPS of 8.84, compared to analyst estimates of 9.14 by -3.28% . Revenue for the quarter reached 49.42B compared to expectations of 48.20B by 2.54% .
The stock price reacted with a -12.22% one-day change and a -18.24% five-day change following the earnings release. These movements reflect market reaction in Elevance Health Inc growth trajectory and strategic initiatives.
ELV Earnings Forecast
Looking ahead, Elevance Health Inc(ELV) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 49.23B and an EPS of 4.94.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 1.46%, while EPS estimates have been Revise Downward by -13.41%. For the upcoming Q3 2025, revenue estimates have been adjusted Revise Upward by 1.42% . These revisions correlate with a -22.09% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Elevance Health Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between ELV's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward

+1.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-13.41%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Upward

+1.42%
In Past 3 Month
Stock Price
Go Down

-22.09%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:196.90B
--
EPS Estimate-Annual FY 2025:29.88
—
Stock Price292.48
ELV Revenue and EPS Performance: A Historical Perspective
Elevance Health Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-07-17,Pre-Market):
EPS: 8.84 (Actual) vs.9.14 (Estimate) (-3.28%)
Revenue: 49.42B (Actual) vs. 48.20B (Estimate) (2.54%)
Price Reaction: -12.22%(1-Day), -18.24%(5-Day)
FY2025Q1 (2025-04-22,Pre-Market):
EPS: 11.97 (Actual) vs.11.97 (Estimate) (0.00%)
Revenue: 48.77B (Actual) vs. 46.25B (Estimate) (5.44%)
Price Reaction: 2.26%(1-Day), 3.69%(5-Day)
FY2024Q4 (2025-01-23,Pre-Market):
EPS: 3.84 (Actual) vs.3.80 (Estimate) (1.05%)
Revenue: 44.99B (Actual) vs. 44.72B (Estimate) (0.61%)
Price Reaction: 2.72%(1-Day), 2.45%(5-Day)
Earnings Reaction
The chart below shows how ELV performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ELV sees a +1.73% change in stock price 10 days leading up to the earnings, and a -1.38% change 10 days following the report. On the earnings day itself, the stock moves by -2.03%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -8.38% on the day following the earnings release and then changed by -6.40% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Elevance Health Inc (ELV) Q2 2025 Earnings Call Summary
Positive
2025-07-17
The earnings call showed strong financial performance with a 15% revenue increase and significant EPS growth. Despite some challenges in Medicaid and ACA margins, the company is taking proactive measures to address these. Share repurchases indicate confidence, and the optimistic guidance suggests future growth. The Q&A section highlighted strategic actions to stabilize markets and improve cost structures, which are positive indicators. Overall, the company's initiatives and financial outlook suggest a positive stock price movement over the next two weeks.
Elevance Health Inc (ELV) Q1 2025 Earnings Call Summary
Neutral
2025-04-23
The earnings report shows strong financial metrics like revenue and EPS growth, but also highlights challenges such as increased costs and membership growth issues. The Q&A section reveals management's confidence in managing costs and growth, but some responses lacked clarity, particularly on risk coding and Medicaid rates. The share repurchase indicates confidence, but the economic pressures on healthcare costs and higher benefit expense ratio offset the positives, leading to a neutral sentiment overall.
Elevance Health Inc (ELV) Q1 2025 Earnings Call Summary
Positive
2025-04-22
The earnings call reflects strong financial metrics with EPS growth over 10%, a 15% increase in operating revenue, and strategic share repurchases indicating confidence. Despite some cost pressures in Medicaid, the overall sentiment remains positive due to robust growth in Carelon services and strategic investments. The Q&A highlighted manageable Medicare costs and strong growth in Carelon services, while management's confidence in trends and strategic initiatives further supports a positive outlook. However, some uncertainties were noted regarding IRA impacts and utilization trends, slightly tempering the sentiment.
Elevance Health, Inc. (ELV) Q3 2024 Earnings Call Summary
Negative
2024-10-17
The earnings call summary and Q&A reveal several negative factors: elevated medical costs in Medicaid, inadequate rate increases, membership loss, and regulatory challenges. Despite revenue growth, the benefit expense ratio increased, and EPS missed expectations. The lack of a share repurchase program and challenges in Medicaid and Medicare Advantage further contribute to a negative outlook. While management is optimistic about future growth, the immediate concerns and uncertainties outweigh the positives, leading to a predicted stock price movement of -2% to -8% over the next two weeks.
Elevance Health, Inc. (ELV) Q2 2024 Earnings Call Summary
Neutral
2024-07-17
The earnings call summary presents a mixed picture. Positive aspects include strong EPS growth, strategic partnerships, and share repurchase plans. However, concerns arise from flat operating revenue, Medicaid membership challenges, and Medicare Advantage funding cuts. The Q&A section highlights constructive state conversations but also notes Medicaid margin compression. The increased guidance and strategic initiatives are offset by flat revenue and healthcare funding concerns, leading to a neutral prediction for stock price movement over the next two weeks.
People Also Watch

ABNB
Airbnb Inc
121.610
USD
+2.80%

SHW
Sherwin-Williams Co
358.090
USD
+0.99%

PH
Parker-Hannifin Corp
752.040
USD
+2.93%

ICE
Intercontinental Exchange Inc
182.740
USD
-1.72%

MO
Altria Group Inc
66.010
USD
+0.52%

WM
Waste Management Inc
232.980
USD
-1.74%

BP
BP PLC
34.070
USD
+0.35%

TT
Trane Technologies PLC
438.950
USD
+2.54%

EQIX
Equinix Inc
787.320
USD
+1.36%

AMT
American Tower Corp
204.620
USD
-0.71%
FAQ

What were the key highlights of ELV’s latest earnings report for FY2025Q2?
ELV reported its FY2025Q2 earnings on 2025-07-17, showcasing a revenue of 49.42B against an estimate of 48.20B, resulting in a 2.54% surprise. The EPS was 8.84, surpassing the expected 9.14 by -3.28% . The stock experienced a -12.22% price change on the earnings day and a -18.24% change over the next five days, reflecting market reactions to the results.

How did ELV’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for ELV for 2025/Q3?

How does ELV’s stock price correlate with earnings forecast revisions?

What should investors expect from ELV’s next earnings report?
